Discontinued — last reported Q2 '21

Non-Current Assets

Investments - Amortized Cost Basis

DexCom Investments - Amortized Cost Basis increased by 0.7% to $219.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 87.8%, from $1.79B to $219.50M. Over 4 years (FY 2020 to FY 2025), Investments - Amortized Cost Basis shows a downward trend with a -41.7% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2017
Last reportedQ2 2021
Metric ID: investments_amortized_cost

Historical Data

13 periods
 Q2 '21Q3 '21Q4 '22Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q4 '25Q1 '26
Value$1.43B$1.25B$1.82B$2.44B$2.60B$2.16B$2.05B$2.18B$1.87B$1.97B$1.79B$218.00M$219.50M
QoQ Change—-12.1%+45.1%+34.4%+6.3%-17.0%-5.1%+6.7%-14.5%+5.6%-9.0%-87.9%+0.7%
YoY Change—————+18.6%—-10.7%-28.1%-8.6%-12.3%-88.9%-87.8%
Range$218.00M – $2.60B
CAGR-46.4%
Avg YoY Growth-31.1%
Median YoY Growth-12.3%

Frequently Asked Questions

What is DexCom's investments - amortized cost basis?
DexCom (DXCM) reported investments - amortized cost basis of $219.50M in Q1 2026.
How has DexCom's investments - amortized cost basis changed year-over-year?
DexCom's investments - amortized cost basis decreased by 87.8% year-over-year, from $1.79B to $219.50M.
What is the long-term trend for DexCom's investments - amortized cost basis?
Over 4 years (2020 to 2025), DexCom's investments - amortized cost basis has grown at a -41.7% compound annual growth rate (CAGR), from $1.89B to $218.00M.